Abilita Bio, Inc. was founded in 2014, and is an innovation-driven biotechnology company focused on leveraging its EMP™ platform and deep membrane protein expertise to enable the drug discovery and development. The company has established several research collaborations with global pharma and biotech partners focused on supporting their drug discovery programs, and has formed multiple strategic partnerships to build its internal R&D pipeline.